These results represent critical milestones for Philogen, as Fibromun has the potential to become second product to successfully complete multinational clinical trials with registration potential
Doxorubicin Hydrochloride Liposome Injection is indicated for the treatment of Ovarian Cancer, AIDS-Related Kaposi's Sarcoma, and Multiple Myeloma
Merck KGaA, Darmstadt, Germany announced the presentation of new oncology data across more than 12 tumor types at ASCO 2025
The approved product has an estimated market size of US$ 106 million for the twelve months ending October 2024, according to IQVIA
Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun
ForDoz Pharma Corporation, USA (ForDoz) received an approval for its ANDA from the USFDA
Doxorubicin Hydrochloride Liposome Injection (RLD Doxil) had estimated annual sales of USD 42 million in the U.S. (IQVIA MAT May 2024)
Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America
Zurletrectinib was developed to treat advanced or metastatic solid tumors harboring NTRK fusion genes
Lilly may be eligible for up to US $ 225m in payments based upon the achievement of pre-specified development, regulatory and commercial milestones
Subscribe To Our Newsletter & Stay Updated
